
The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Current Issue | New England Journal of Medicine
Nov 27, 2025 · Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 21).
Recently Published - The New England Journal of Medicine
Nov 29, 2025 · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).
Original Article - The New England Journal of Medicine
Explore Original Article articles from The New England Journal of Medicine
About NEJM - The New England Journal of Medicine
The New England Journal of Medicine (NEJM) is recognized as the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed ...
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
May 11, 2025 · Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without …
New Manuscripts | NEJM Author Center
NEJM uses highly rigorous editorial, peer, and statistical review processes to evaluate manuscripts for scientific accuracy, novelty, and importance.
NEJM Author Center
NEJM seeks submissions of original research, reviews, case reports, and commentaries that improve patient care and clinical practice, or that offer new information about the biology of disease.
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …
Perioperative Durvalumab in Gastric and Gastroesophageal Junction ...
Jun 1, 2025 · Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates …